NeuroLife, the market-facing brand of ActivateNeuro, Inc., has launched out of a strategic partnership between Battelle and The NeuroTech Institute to develop non-invasive neurotechnology for stroke and spinal cord injury rehabilitation.
Related: Nanoflex Robotics Awarded €12.5 Million from the EIC Accelerator
The company’s core product is a wearable sleeve that reads electrical signals from muscles and nerves, interprets movement intent, and delivers targeted stimulation to support hand and arm recovery during therapy. The platform combines high-density neuromuscular sensing, intelligent decoding, and adaptive stimulation to deliver personalized, signal-driven rehab in real time.
NeuroLife closed a $2.9 million seed round and plans to seek FDA clearance for its platform technology.
Jon Snyder, CEO of NeuroLife, said: “NeuroLife represents a focused step forward in how rehabilitation can evolve. Our goal is to develop a non-invasive platform that supports functional hand and arm use by making therapy more personalized, responsive and aligned with how the body naturally moves.”
Matt McFarland, VP of commercial strategy at Battelle, said: “Battelle has a long history of translating scientific innovation into real-world impact. Our collaboration with NTI and the formation of NeuroLife advances neurotechnology from foundational research into clinical and commercial development. NeuroLife brings the rigor of Battelle’s research capabilities into a platform built for clinical environments and patient impact.”
